《Datamonitor：2026食管癌诊疗全景解析报告：从流行病学趋势到免疫治疗新突破（英文版）（21页）.pdf》由会员分享，可在线阅读，更多相关《Datamonitor：2026食管癌诊疗全景解析报告：从流行病学趋势到免疫治疗新突破（英文版）（21页）.pdf（21页珍藏版）》请在三个皮匠报告上搜索。

1、Market Spotlight Esophageal Cancer121 Jan,2026Copyright 2026 Evaluate,a Norstella company(Unauthorized photocopying prohibited)Market Spotlight:Esophageal Cancer Last Reviewed:21 Jan,2026 Market Spotlight Esophageal Cancer221 Jan,2026Copyright 2026 Evaluate,a Norstella company(Unauthorized photocopy

2、ing prohibited)Latest TakeawaysDatamonitor Healthcare estimates that in 2025,there were 627,800 incident cases of esophageal cancer worldwide,and expects that number to increase to 648,100 incident cases by 2030.Incidence is higher in males compared to females,and is highest in the Asia region.The a

3、pproved drugs in the esophageal cancer space target programmed death-1 receptor(PD-1),reactive oxygen species/free radicals,cytotoxic T-lymphocyte antigen 4(CTLA4),and the immune system.These drugs are administered via the intravenous route.Immunotherapy-based regimens are increasingly established a

4、cross first-line and later-line settings,particularly in esophageal squamous cell carcinoma,reflecting a shift away from chemotherapy-only backbones.The largest proportion of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II.Therapies in development for es

5、ophageal cancer focus on a wide variety of targets.The majority of pipeline drugs are administered intravenously,with the remainder being oral,surgical implantation,intramuscular,intratumoral,and intranodal formulations.High-impact upcoming events in the esophageal cancer space include anticipated r

6、egulatory approval decisions in Japan for both Telomelysin and Tevimbra.Market Spotlight Esophageal Cancer321 Jan,2026Copyright 2026 Evaluate,a Norstella company(Unauthorized photocopying prohibited)Disease BackgroundEsophageal cancer is a malignancy arising from the epithelial cells lining the esop